In the interview, Nazari provided comprehensive insights into PDTs, describing them as FDA-approved, software-based treatments that package cognitive behavioral therapy into digital experiences including mobile apps, web applications, tablets, and even virtual reality platforms. These digital interventions serve as both alternatives and complements to traditional therapies, offering enhanced accessibility for patients in both urban and rural environments.

‍

Nazari emphasized the critical importance of the Access to Prescription Digital Therapeutics Act for industry growth, noting that formulary coverage remains the largest barrier to PDT adoption. He highlighted that CMS approval would likely drive private insurers to follow suit, significantly broadening patient access to these innovative treatments.

‍

The discussion showcased CaryHealth's comprehensive digital infrastructure capabilities, with Nazari explaining how the company has built end-to-end solutions for seamless patient onboarding, education, and therapeutic delivery. CaryHealth's white-labeled platform creates cohesive user experiences from prescription receipt through payment processing and therapeutic handoff.

‍

Looking toward the future, Nazari outlined expanding opportunities for pharmacists as digital prescriptions become standard care. Beyond answering increased patient questions about these new treatments, pharmacists will play pivotal roles in Remote Therapeutic Monitoring (RTM), helping monitor PDT efficacy and becoming more intimately involved in patient care outcomes.